These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8856366)

  • 1. Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS.
    Howell AL; Taylor TH; Miller JD; Groveman DS; Eccles EH; Zacharski LR
    Int J Clin Lab Res; 1996; 26(2):124-31. PubMed ID: 8856366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.
    Stone AL; Melton DJ; Lewis MS
    Glycoconj J; 1998 Jul; 15(7):697-712. PubMed ID: 9881776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection.
    Rider CC
    Glycoconj J; 1997 Aug; 14(5):639-42. PubMed ID: 9298697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
    Cziraky MJ; Spinler SA
    Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity.
    Lopalco L; Ciccomascolo F; Lanza P; Zoppetti G; Caramazza I; Leoni F; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):787-93. PubMed ID: 7986584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
    Padilla A; Gray E; Pepper DS; Barrowcliffe TW
    Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical potential of low molecular weight heparins.
    Levine MN; Hirsh J
    Baillieres Clin Haematol; 1990 Jul; 3(3):545-54. PubMed ID: 2176904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS.
    Shaunak S; Thornton M; John S; Teo I; Peers E; Mason P; Krausz T; Davies DS
    AIDS; 1998 Mar; 12(4):399-409. PubMed ID: 9520170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin).
    Pèrez-Requejo JL; Lucena-Solano O; Pérez-García M; Santarelli MT
    Thromb Res; 1997 Feb; 85(3):259-65. PubMed ID: 9058500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?
    Bucy RP; Kilby JM
    AIDS; 2001 Feb; 15 Suppl 2():S36-42. PubMed ID: 11424975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of venous thromboembolism with low molecular weight heparins.
    Hull RD; Pineo GF
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1095-103. PubMed ID: 1328143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of low molecular weight heparins: knowledge to date and their application to therapy.
    Hull RD; Pineo GF
    Semin Thromb Hemost; 1994; 20(4):339-44. PubMed ID: 7899865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of human immunodeficiency viral replication by pine cone extracts.
    Lai PK; Donovan J; Takayama H; Sakagami H; Tanaka A; Konno K; Nonoyama M
    AIDS Res Hum Retroviruses; 1990 Feb; 6(2):205-17. PubMed ID: 1691654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic use of low-molecular-weight heparins.
    Hull RD; Pineo GF
    Haemostasis; 1993 Mar; 23 Suppl 1():2-9. PubMed ID: 8388352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
    Fox KA
    Am J Cardiol; 1999 Sep; 84(5A):26M-31M. PubMed ID: 10505540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration.
    Schrader J; Stibbe W; Armstrong VW; Kandt M; Muche R; Köstering H; Seidel D; Scheler F
    Kidney Int; 1988 Apr; 33(4):890-6. PubMed ID: 2838681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs.
    Witvrouw M; De Clercq E
    Gen Pharmacol; 1997 Oct; 29(4):497-511. PubMed ID: 9352294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
    Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1.
    Sperber K; Louie M; Kraus T; Proner J; Sapira E; Lin S; Stecher V; Mayer L
    Clin Ther; 1995; 17(4):622-36. PubMed ID: 8565026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why low molecular weight heparin?
    Mammen EF
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():1-4. PubMed ID: 1962897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.